Imatge de la portada

Assessment of Sedative Activity of Lonicerin: In Vivo Approach With Pharmacokinetics and Molecular Docking

Guardat en:
Publicat a:Brain and Behavior vol. 15, no. 5 (May 1, 2025)
Autor principal: Eity, Tanzila Akter
Altres autors: Bhuia, Md. Shimul, Chowdhury, Raihan, Sheikh, Salehin, Ansari, Siddique Akber, Ahammed, Nowreen Tabassum, Kamli, Hossam, Islam, Muhammad Torequl
Publicat:
John Wiley & Sons, Inc.
Matèries:
Bangladesh
Insomnia
Ligands
Sleep
Animals
Albinism
Natural products
Energy consumption
Benzodiazepines
Drug dosages
Variance analysis
Accés en línia:Citation/Abstract
Full Text
Full Text - PDF
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
Resum:ABSTRACT Background: Lonicerin (LON) has been identified to have different biological properties, such as anticancer, anti‐inflammatory, immunomodulatory, antibacterial, antimicrobial, and neuroprotective. This study aims to assess the sedative effect of LON in Swiss albino mice, which is yet to be discovered. Materials and Methods: Mice were treated with two different doses of LON (5 and 10 mg/kg) and 2 mg/kg of diazepam (DZP), which is the referral GABAergic medication, and the latency time and sleeping duration of animals were observed. A computational study was also conducted to evaluate the docking scores and display the binding sites of LON and receptor (GABAA α1 and β2 subunits). The study also investigated the pharmacokinetics and drug‐likeness properties of LON along with toxicological analysis by using SwissADME and Protox‐3 software, respectively. Results: Findings revealed that the higher concentration of LON reduced the latency (9.86 ± 1.44 min) and increased the sleep duration (191.29 ± 7.43 min) compared to the lower concentration. Besides, the combination group of LON and DZP showed the lowest latency (6.17 ± 0.82 min) and highest sleeping time (219.00 ± 6.39 min). In the in silico study, LON exhibited a strong docking score (−8.1 kcal/mol) with the macromolecules, which is closer to the binding affinity of DZP (–8.3 kcal/mol), indicating that LON could show strong sedative activity by binding with the GABAA receptor. Computational toxicity analysis revealed that LON is non‐hepatotoxic, non‐neurotoxic, noncarcinogenic, noncytotoxic, non‐ecotoxic, and non‐mutagenic. Conclusion: Therefore, LON may be effective for the treatment of insomnia in the near future.
ISSN:2162-3279
DOI:10.1002/brb3.70524
Font:Health & Medical Collection